Intratumoral immunotherapy agents - Diakonos Oncology
Alternative Names: Intratumoral injection - Diakonos OncologyLatest Information Update: 24 Oct 2023
At a glance
- Originator Diakonos Oncology
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bone cancer; Head and neck cancer
Most Recent Events
- 06 Oct 2023 Diakonos Oncology has patent protection for a combination of immunotherapy agents designed to be injected intratumorally (Diakonos Oncology website, October 2023)
- 06 Oct 2023 Preclinical trials in Bone cancer in USA (Intratumoural) before October 2023 (Diakonos Oncology pipeline, October 2023)
- 06 Oct 2023 Preclinical trials in Head and neck cancer in USA (Intratumoural) before October 2023 (Diakonos Oncology pipeline, October 2023)